Abacavir Hypersensitivity — HLA-B*57:01, the variant that makes abacavir an HIV treatment for most but a potentially life-threatening hypersensitivity reaction for the 5-8% of Europeans who carry it.
Whole genome sequencing provides complete HLA class I typing — including the HLA-B*57:01 allele that the FDA mandates screening for before abacavir is prescribed — alongside all other pharmacogenomic relevant HLA alleles.
Abacavir Hypersensitivity — HLA-B*57:01
Abacavir (Ziagen) is a nucleoside reverse transcriptase inhibitor (NRTI) used as a core component of combination antiretroviral therapy for HIV infection. Approximately 5-8% of patients prescribed abacavir without prior HLA-B*57:01 screening develop a potentially life-threatening hypersensitivity reaction (HSR) characterized by fever, rash, gastrointestinal symptoms, and malaise beginning within the first 6 weeks of therapy. In patients who develop HSR and then inadvertently re-challenge with abacavir — for example, if the diagnosis was not clearly documented — the reaction can be severe and rapidly fatal, with acute hypotension and multi-organ failure.
The association between HLA-B*57:01 and abacavir hypersensitivity is one of the strongest pharmacogenomic associations in medicine. HLA-B*57:01 carriers who receive abacavir have approximately a 50-60% risk of developing HSR, compared to approximately 0-1% in non-carriers. The mechanism involves the HLA-B*57:01 protein presenting abacavir or its metabolites as part of the peptide-binding groove to CD8+ T cells, triggering a polyclonal cytotoxic T cell response. HLA-B*57:01 is present in approximately 5-8% of European ancestry individuals, 1-3% of African ancestry individuals, and under 1% of Asian ancestry individuals, making screening particularly impactful in European-ancestry HIV populations.
The FDA added a boxed warning to abacavir in 2008 requiring HLA-B*57:01 screening before or at the time of initiating abacavir therapy. WHO HIV treatment guidelines likewise recommend HLA-B*57:01 screening before abacavir use. Implementation of universal pre-treatment screening has reduced the incidence of immunologically confirmed abacavir HSR by approximately 50%. The test is standard of care in HIV treatment in the United States, European Union, and increasingly in low-and-middle-income countries. HLA-B*57:01 is also associated with flucloxacillin-induced liver injury and carbamazepine hypersensitivity risk, making complete HLA typing — as provided by whole genome sequencing — broadly valuable in patients with complex medication regimens.
Single HLA-B*57:01 commercial tests exist and are standard of care before abacavir. What whole genome sequencing adds is comprehensive HLA typing — covering HLA-B*15:02, HLA-B*58:01, and other clinically actionable HLA alleles alongside B*57:01 in a single test.
Complete HLA typing covers multiple life-critical drug hypersensitivity alleles in one result
HLA-B*57:01 is just one of several HLA alleles with documented drug hypersensitivity associations. HLA-B*15:02 (carbamazepine-SJS/TEN in Southeast Asian populations), HLA-B*58:01 (allopurinol-SJS/TEN), HLA-B*57:01 (flucloxacillin liver injury), and HLA-A*31:01 (carbamazepine hypersensitivity in Europeans) are all clinically actionable alleles with distinct geographic distributions and drug-specific associations. A patient receiving multiple medications may have multiple relevant HLA pharmacogenomic considerations. Whole genome sequencing performs complete high-resolution HLA class I and II typing — providing the complete HLA pharmacogenomic profile in a single test rather than ordering separate single-allele tests for each relevant drug.
HLA-B*57:01 status is a permanent result — the same genome that predicts abacavir risk also informs lifelong prescribing decisions
Unlike many clinical laboratory results that require periodic re-testing, HLA genotype is fixed at birth and never changes. A HLA-B*57:01 result obtained once — whether from a targeted test or whole genome sequencing — is valid for life. The abacavir prescribing contraindication applies regardless of HIV treatment stage or co-morbidities. For patients with HIV who may change treatment regimens over many years, having the HLA genotype permanently documented in the medical record ensures that abacavir-containing regimens are avoided at every future treatment decision point without requiring repeat testing.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Abacavir Hypersensitivity — HLA-B*57:01 and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
